Mason David P, Solovera-Rozas Maria, Feng Jingyuan, Rajeswaran Jeevanantham, Thuita Lucy, Murthy Sudish C, Budev Marie M, Mehta Atul C, Haug Marcus, McNeill Ann M, Pettersson Gösta B, Blackstone Eugene H
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio 44195, USA.
J Heart Lung Transplant. 2007 Nov;26(11):1155-62. doi: 10.1016/j.healun.2007.08.006.
Renal failure requiring dialysis after lung transplantation represents a major source of morbidity for patients and compromises their quality of life. We sought to ascertain the prevalence of dialysis after lung transplantation and to identify risk factors for its occurrence. We also assessed outcomes after institution of dialysis.
From our program's inception in February 1990 until January 2005, 425 patients underwent lung transplantation. Data on dialysis occurrence, timing, management and outcome were extracted from the Unified Transplant Database, patient follow-up and medical record review.
Thirty-seven patients developed a need for dialysis, a prevalence of 0.6%, 4%, 9%, 13%, 16% and 19%, at 30 days and 1, 3, 5, 7 and 9 years after transplant, respectively. Lower creatinine clearance (p = 0.03) and greater recipient height (p = 0.0002) increased the risk for dialysis, whereas donor blood type O (p = 0.001) and head trauma as donor cause of death (p = 0.01) lowered it. Higher doses of calcineurin inhibitors correlated with the period of highest risk for dialysis. Median survival of patients requiring dialysis was 5 months, considerably lower than expected. Four patients underwent renal transplantation, 3 of whom were still alive 3, 6 and 9 months later.
Dialysis after lung transplantation is common and cumulative over time. Risk factors for its development may be modifiable because they appear to be linked to nephrotoxicity secondary to immunosuppression. The low threshold for creatinine clearance appears to be 50 ml/min/1.73 m(2). Survival after institution of dialysis is poor, highlighting the need for prevention. Renal transplantation may be a reasonable therapeutic option.
肺移植后需要透析的肾衰竭是患者发病的主要原因,会影响其生活质量。我们试图确定肺移植后透析的发生率,并找出其发生的风险因素。我们还评估了开始透析后的预后情况。
从我们的项目于1990年2月启动至2005年1月,共有425例患者接受了肺移植。从统一移植数据库、患者随访及病历审查中提取有关透析发生情况、时间、管理及预后的数据。
37例患者出现了透析需求,在移植后30天及1、3、5、7和9年时的发生率分别为0.6%、4%、9%、13%、16%和19%。较低的肌酐清除率(p = 0.03)和较高的受者身高(p = 0.0生率,而供者血型为O型(p = 0.001)以及供者因头部外伤死亡(p = 0.01)则降低了发生率。更高剂量的钙调神经磷酸酶抑制剂与透析风险最高的时期相关。需要透析的患者的中位生存期为5个月,远低于预期。4例患者接受了肾移植,其中3例在3、6和9个月后仍存活。
肺移植后透析很常见且随时间累积。其发生的风险因素可能是可改变的,因为它们似乎与免疫抑制继发的肾毒性有关。肌酐清除率的低阈值似乎为50 ml/min/1.73 m²。开始透析后的生存率很低,这凸显了预防的必要性。肾移植可能是一种合理的治疗选择。 0果。更高剂量的钙调神经磷酸酶抑制剂与透析风险最高的时期相关。需要透析的患者的中位生存期为5个月,远低于预期。4例患者接受了肾移植,其中3例在3、6和9个月后仍存活。
肺移植后透析很常见且随时间累积。其发生的风险因素可能是可改变的,因为它们似乎与免疫抑制继发的肾毒性有关。肌酐清除率的低阈值似乎为50 ml/min/1.73 m²。开始透析后的生存率很低,这凸显了预防的必要性。肾移植可能是一种合理的治疗选择。 002)会增加透析的风